10-Q
falseQ1Organogenesis Holdings Inc.0001661181--12-31MAP4DP5Yhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentNet 0001661181 2022-01-01 2022-03-31 0001661181 2021-01-01 2021-03-31 0001661181 2022-03-31 0001661181 2021-12-31 0001661181 2021-03-31 0001661181 2021-01-01 2021-12-31 0001661181 2021-09-30 0001661181 2020-09-17 0001661181 2021-08-06 2021-08-06 0001661181 2022-05-01 0001661181 2020-12-31 0001661181 us-gaap:DevelopedTechnologyRightsMember 2022-03-31 0001661181 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0001661181 orgo:CustomerRelationshipMember 2022-03-31 0001661181 us-gaap:NoncompeteAgreementsMember 2022-03-31 0001661181 orgo:IndependentSalesAgencyNetworkMember 2022-03-31 0001661181 us-gaap:PatentsMember 2022-03-31 0001661181 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001661181 us-gaap:BuildingMember 2022-03-31 0001661181 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001661181 us-gaap:ConstructionInProgressMember 2022-03-31 0001661181 us-gaap:CommonClassAMember orgo:TwoThousandEighteenStockIncentivePlanMember 2022-03-31 0001661181 orgo:LiquidityLoanAndOptionLoansMember srt:MinimumMember 2022-03-31 0001661181 orgo:LiquidityLoanAndOptionLoansMember srt:MaximumMember 2022-03-31 0001661181 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001661181 us-gaap:OptionMember 2022-03-31 0001661181 orgo:LicenseAgreementUniversityMember 2022-03-31 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember 2022-03-31 0001661181 srt:MaximumMember 2022-03-31 0001661181 srt:MinimumMember 2022-03-31 0001661181 orgo:FleetLeaseMember 2022-03-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:PrincipalMember 2022-03-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:CommonAreaMaintenanceMember 2022-03-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:PrincipalInterestAndCAMMember 2022-03-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember 2022-03-31 0001661181 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001661181 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001661181 orgo:CustomerRelationshipMember 2021-12-31 0001661181 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001661181 orgo:IndependentSalesAgencyNetworkMember 2021-12-31 0001661181 us-gaap:PatentsMember 2021-12-31 0001661181 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001661181 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001661181 us-gaap:BuildingMember 2021-12-31 0001661181 us-gaap:ConstructionInProgressMember 2021-12-31 0001661181 orgo:LicenseAgreementUniversityMember 2021-12-31 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember 2021-12-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:PrincipalMember 2021-12-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:CommonAreaMaintenanceMember 2021-12-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember orgo:PrincipalInterestAndCAMMember 2021-12-31 0001661181 orgo:AccruedButUnpaidLeaseObligationMember 2021-12-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001661181 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001661181 orgo:TwoThousandThreeAndTwoThousandEighteenStockIncentivePlanMember us-gaap:OptionMember 2022-01-01 2022-03-31 0001661181 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001661181 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001661181 us-gaap:OptionMember 2022-01-01 2022-03-31 0001661181 orgo:LicenseAgreementUniversityMember 2022-01-01 2022-03-31 0001661181 srt:MinimumMember orgo:TwoThousandThreeAndTwoThousandEighteenStockIncentivePlanMember 2022-01-01 2022-03-31 0001661181 srt:MaximumMember orgo:TwoThousandThreeAndTwoThousandEighteenStockIncentivePlanMember 2022-01-01 2022-03-31 0001661181 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001661181 us-gaap:FairValueInputsLevel3Member orgo:EarnoutLiabilityMember 2022-01-01 2022-03-31 0001661181 orgo:SurgicalAndSportsMedicineMember 2022-01-01 2022-03-31 0001661181 orgo:AdvancedWoundCareMember 2022-01-01 2022-03-31 0001661181 orgo:InternationalMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-03-31 0001661181 orgo:EmployeeCostMember 2022-01-01 2022-03-31 0001661181 orgo:OtherMember 2022-01-01 2022-03-31 0001661181 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001661181 orgo:TwoSevenFiveDanRoadSpeLlcMember 2022-01-01 2022-03-31 0001661181 orgo:TwoThousandNineteenCreditAgreementMember 2022-01-01 2022-03-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001661181 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001661181 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001661181 orgo:LicenseAgreementUniversityMember 2021-01-01 2021-03-31 0001661181 orgo:OptionLoansMember 2021-01-01 2021-03-31 0001661181 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001661181 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001661181 us-gaap:FairValueInputsLevel3Member orgo:EarnoutLiabilityMember 2021-01-01 2021-03-31 0001661181 orgo:SurgicalAndSportsMedicineMember 2021-01-01 2021-03-31 0001661181 orgo:AdvancedWoundCareMember 2021-01-01 2021-03-31 0001661181 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001661181 orgo:LiquidityloanmemberMember 2020-12-31 0001661181 orgo:OptionLoansMember 2020-12-31 0001661181 orgo:PrincipalInterestAndCAMMember orgo:AccruedButUnpaidLeaseObligationMember 2020-12-31 0001661181 orgo:CpnBiosciencesLlcMember 2020-09-17 0001661181 orgo:TermLoanMember orgo:TwoThousandNineteenCreditAgreementMember 2019-03-14 2019-03-14 0001661181 orgo:TwoThousandNineteenCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2019-03-14 2019-03-14 0001661181 us-gaap:RevolvingCreditFacilityMember orgo:TwoThousandNineteenCreditAgreementMember 2019-03-14 0001661181 orgo:TwoThousandNineteenCreditAgreementMember orgo:TermLoanMember 2019-03-14 0001661181 orgo:RedeemableCommonStockMember orgo:NutechAcquisitionMember 2019-03-01 2019-03-24 0001661181 us-gaap:CommonClassAMember 2019-03-01 2019-03-24 0001661181 orgo:TwoSevenFiveDanRoadSpeLlcMember 2021-08-11 2021-08-11 0001661181 orgo:TwoSevenFiveDanRoadSpeLlcMember 2021-08-11 0001661181 orgo:LaJollaRestructuringMember 2020-10-21 0001661181 orgo:CpnBiosciencesLlcMember 2020-09-17 2020-09-17 0001661181 orgo:TotalConsiderationIncludingHoldbackMember orgo:CpnBiosciencesLlcMember 2020-09-17 2020-09-17 0001661181 orgo:TotalConsiderationIncludingHoldbackMember orgo:CpnBiosciencesLlcMember us-gaap:CommonStockMember 2020-09-17 2020-09-17 0001661181 us-gaap:RevolvingCreditFacilityMember orgo:TwoThousandTwentyOneCreditAgreementMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember orgo:TermLoanMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember orgo:EuroDollarLoansMember srt:MinimumMember orgo:ApplicableMarginMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember orgo:EuroDollarLoansMember srt:MaximumMember orgo:ApplicableMarginMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember orgo:AbrLoansMember srt:MinimumMember orgo:ApplicableMarginMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember orgo:AbrLoansMember srt:MaximumMember orgo:ApplicableMarginMember 2021-08-06 0001661181 orgo:TwoThousandTwentyOneCreditAgreementMember 2021-08-06 2021-08-06 0001661181 orgo:TwoThousandNineteenCreditAgreementMember 2021-08-06 2021-08-06 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember orgo:SeptemberThreeZeroTwoThousandTwentyTwoThroughAndIncludingJuneThreeZeroTwoThousandTwentyThreeMember 2021-08-06 2021-08-06 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember orgo:SeptemberThreeZeroTwoThousandTwentyThreeThroughAndIncludingJuneThreeZeroTwoThousandTwentyFiveMember 2021-08-06 2021-08-06 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember orgo:SeptemberThreeZeroTwoThousandTwentyFiveAndTheLastDayOfEachQuarterThereafterUntilAugustSixTwoThousandTwentySixMember 2021-08-06 2021-08-06 0001661181 orgo:TermLoanMember orgo:TwoThousandTwentyOneCreditAgreementMember orgo:SeptemberThreeZeroTwoThousandTwentyOneThroughAndIncludingJuneThreeZeroTwoThousandTwentyTwoMember 2021-08-06 2021-08-06 0001661181 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember orgo:TwoThousandTwentyOneCreditAgreementMember 2021-08-06 2021-08-06 0001661181 us-gaap:RevolvingCreditFacilityMember orgo:TwoThousandTwentyOneCreditAgreementMember srt:MaximumMember 2021-08-06 2021-08-06 0001661181 orgo:BirminghamRestructuringMember 2022-03-09 0001661181 orgo:EmployeeCostMember orgo:BirminghamRestructuringMember 2022-03-09 0001661181 orgo:OtherMember orgo:BirminghamRestructuringMember 2022-03-09 0001661181 orgo:PaymentOfHoldbackMember orgo:CpnBiosciencesLlcMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001661181 orgo:PaymentOfHoldbackMember orgo:CpnBiosciencesLlcMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001661181 us-gaap:CommonStockMember 2021-12-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001661181 us-gaap:RetainedEarningsMember 2021-12-31 0001661181 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001661181 us-gaap:FairValueInputsLevel3Member orgo:EarnoutLiabilityMember 2021-12-31 0001661181 us-gaap:FairValueInputsLevel3Member orgo:EarnoutLiabilityMember 2022-03-31 0001661181 orgo:EmployeeCostMember 2021-12-31 0001661181 orgo:OtherMember 2021-12-31 0001661181 orgo:EmployeeCostMember 2022-03-31 0001661181 orgo:OtherMember 2022-03-31 0001661181 us-gaap:CommonStockMember 2022-03-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001661181 us-gaap:RetainedEarningsMember 2022-03-31 0001661181 us-gaap:CommonStockMember 2020-12-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001661181 us-gaap:RetainedEarningsMember 2020-12-31 0001661181 orgo:EarnoutLiabilityMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001661181 orgo:EarnoutLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001661181 us-gaap:CommonStockMember 2021-03-31 0001661181 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001661181 us-gaap:RetainedEarningsMember 2021-03-31 iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Day iso4217:USD xbrli:shares orgo:Segments orgo:Employees
Table of Contents
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarter
ly
Period Ended March 31, 2022
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number:
001-37906
 
 
ORGANOGENESIS HOLDINGS INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 
 
Delaware
 
98-1329150
(State or Other Jurisdiction of
 
(I.R.S. Employer
Incorporation or Organization)
 
Identification No.)
 
85 Dan Road
Canton, MA
 
02021
(Address of principal executive offices)
 
(Zip Code)
(781)
575-0775
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Class A Common Stock, $0.0001 par value
 
ORGO
 
Nasdaq
Capital Market
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange
Act.

 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
     Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No  
The number of shares of the registrant’s Class A common stock outstanding as of May 1, 2022 was 129,130,179.
 
 
 

Table of Contents
Organogenesis Holdings Inc.
Quarterly Report on Form
10-Q
For the Quarterly Period Ended March 31, 2022
Table of Contents
 
 
  
Page
 
  
 
4
 
Item 1.
 
  
 
4
 
 
  
 
4
 
 
  
 
5
 
 
  
 
6
 
 
  
 
7
 
 
  
 
8
 
Item 2.
 
  
 
22
 
Item 3.
 
  
 
31
 
Item 4.
 
  
 
31
 
  
 
32
 
Item 1.
 
  
 
32
 
Item 1A
 
  
 
33
 
Item 2.
 
  
 
33
 
Item 3.
 
  
 
33
 
Item 4.
 
  
 
33
 
Item 5.
 
  
 
33
 
Item 6.
 
  
 
34
 
  
 
35
 
 
2

Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on
Form 10-Q
(this “Form
10-Q”)
contains forward-looking statements. These statements may relate to, but are not limited to, expectations of our future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities and the effects of competition, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. These risks and other factors include, but are not limited to, those listed under “Risk Factors.” In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “intend,” “potential,” “might,” “would,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Form
10-Q
may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and discussed elsewhere in this Form
10-Q
and in “Part I, Item 1A—Risk Factors” in our Annual Report on Form
10-K
for the year ended December 31, 2021. These forward-looking statements speak only as of the date of this Form
10-Q.
Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this
Form 10-Q.
As used herein, except as otherwise indicated by context, references to “we,” “us,” “our,” “the Company,” “Organogenesis” and “ORGO” will refer to Organogenesis Holdings Inc. and its subsidiaries.
 
3

Table of Contents
PART I—FINANCIAL INFORMATION
Item 1. Unaudited Consolidated Financial Statements.
ORGANOGENESIS HOLDINGS INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(amounts in thousands, except share and per share data)
 
 
  
March 31,
 
 
December 31,
 
 
  
2022
 
 
2021
 
Assets
                
Current assets:
                
Cash
 and cash equivalents
   $ 107,897     $ 113,929  
Restricted cash
     605       599  
Accounts receivable, net
     79,477       82,460  
Inventory
, net
     22,737       25,022  
Prepaid expenses and other current assets
     7,135       4,969  
    
 
 
   
 
 
 
Total current assets
     217,851       226,979  
Property and equipment, net
     84,268       79,160  
Intangible assets, net
     24,452       25,673  
Goodwill
     28,772       28,772  
Operating lease
right-of-use
assets, net
     47,468       49,144  
Deferred tax asset, net
     31,994       31,994  
Other assets
     1,467       1,537  
    
 
 
   
 
 
 
Total assets
   $ 436,272     $ 443,259  
    
 
 
   
 
 
 
Liabilities and Stockholders’ Equity
                
Current liabilities:
                
D
eferred acquisition consideration
   $ 1,436     $ 1,436  
Current portion of term loan
     3,126       2,656  
F
inance lease obligations
     101       200  
Current portion of operating lease obligations
     11,775       11,785  
Accounts payable
     27,935       29,339  
Accrued expenses and other current liabilities
     32,419       36,589  
    
 
 
   
 
 
 
Total current liabilities
     76,792       82,005  
Term loan, net of current portion
     69,869       70,769  
Operating lease obligations, net of current portion
     45,323       46,893  
Other liabilities
     1,060       1,557  
    
 
 
   
 
 
 
Total liabilities
     193,044       201,224  
    
 
 
   
 
 
 
Commitments and contingencies (Note 18)
                
Stockholders’ equity:
                
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued
     —         —    
Common stock, $0.0001 par value; 400,000,000 shares authorized; 129,615,732 and 129,408,740 shares issued; 128,887,184 and 128,680,192 shares outstanding at March 31, 2022 and December 31, 2021, respectively.
     13       13  
Additional
paid-in
capital
     303,261       302,155  
Accumulated deficit
     (60,046     (60,133
    
 
 
   
 
 
 
Total stockholders’ equity
     243,228       242,035  
    
 
 
   
 
 
 
Total liabilities and stockholders’ equity
   $ 436,272     $ 443,259  
    
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited consolidated financial statements.
 
4

ORGANOGENESIS HOLDINGS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(amounts in thousands, except share and per share data)

 
 
  
Three Months Ended

March 31,
 
 
  
2022
 
 
2021
 
Net revenue
   $ 98,117     $ 102,552  
Cost of goods sold
     25,080       25,495  
    
 
 
   
 
 
 
Gross profit
     73,037       77,057  
Operating expenses:
                
Selling, general and administrative
     63,578       58,232  
Research and development
     8,587       6,209  
    
 
 
   
 
 
 
Total operating expenses
     72,165       64,441  
    
 
 
   
 
 
 
Income from operations
     872       12,616  
    
 
 
   
 
 
 
Other expense, net:
                
Interest expense
     (737     (2,470
Other expense, net
     (3     (3
    
 
 
   
 
 
 
Total other expense, net
     (740     (2,473
    
 
 
   
 
 
 
Net income before income taxes
     132       10,143  
Income tax expense
     (45     (200
    
 
 
   
 
 
 
Net income
   $ 87     $ 9,943  
    
 
 
   
 
 
 
Net income, per share:
                
Basic
   $ 0.00     $ 0.08  
    
 
 
   
 
 
 
Diluted
   $ 0.00     $ 0.07  
    
 
 
   
 
 
 
Weighted-average common shares outstanding
                
Basic
     128,788,721       127,870,065  
    
 
 
   
 
 
 
Diluted
     132,805,154       133,451,950  
    
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited consolidated financial statements.
 
5

Table of Contents
ORGANOGENESIS HOLDINGS INC.
CONSOLIDATED STATEMENTS STOCKHOLDERS’ EQUITY
(unaudited)
(amounts in thousands, except share data)

 
 
  
Three Months Ended March 31, 2022
 
 
  
 
 
  
 
 
  
Additional
 
 
 
 
 
 
 
 
  
Common Stock
 
  
Paid-in
 
 
Accumulated
 
 
Total
 
 
  
Shares
 
  
Amount
 
  
Capital
 
 
Deficit
 
 
Stockholders’ Equity
 
Balance as of December 31, 2021
     128,680,192      $ 13      $ 302,155     $ (60,133   $ 242,035  
Exercise of stock options
     86,121        —          291       —         291  
Vesting of RSUs, net of shares surrendered to pay taxes
     120,871        —          (488     —         (488
Stock-based compensation expense
     —          —          1,303       —         1,303  
Net income
     —          —          —         87       87  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance as of March 31, 2022
     128,887,184        13        303,261       (60,046     243,228  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
 
 
  
Three Months Ended March 31, 2021
 
 
  
 
 
  
 
 
  
Additional
 
 
 
 
 
 
 
 
  
Common Stock
 
  
Paid-in
 
 
Accumulated
 
 
Total
 
 
  
Shares
 
  
Amount
 
  
Capital
 
 
Deficit
 
 
Stockholders’ Equity
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance as of December 31, 2020 
     127,731,833        13        296,830       (155,035     141,808  
Exercise of stock options
     285,344        —          984       —         984  
Vesting of RSUs, net of shares surrendered to pay taxes
     85,078        —          (417     —         (417
Stock-based compensation expense
     —          —          698       —         698  
Net income
     —          —          —         9,943       9,943  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
Balance as of March 31, 2021 
     128,102,255      $ 13      $ 298,095     $ (145,092   $ 153,016  
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these unaudited consolidated financial statements.
 
6
ORGANOGENESIS HOLDINGS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(amounts in thousands)

 
 
  
Three Months Ended

March 31,
 
 
  
2022
 
 
2021
 
Cash flows from operating activities:
                
Net income
   $ 87     $ 9,943  
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
                
Depreciation
     1,347       1,010  
Amortization of intangible assets
     1,221       1,243  
Amortization of operating lease
right-of-use
assets
     1,847       1,129  
Non-cash
interest expense
     108       72  
Deferred interest expense
     151       525  
Provision recorded for doubtful accounts
     40       921  
Loss on disposal of property and equipment
              239  
Adjustment for excess and obsolete inventories
     2,205       2,290  
Stock-based compensation
     1,303       698  
Change in fair value of Earnout liability
              (296
Changes in operating assets and liabilities:
                
Accounts receivable
     2,942       (16,119
Inventory
     80       (4,212
Prepaid expenses and other current assets
     (2,165     (622
Operating leases
     (1,751     (1,210
Accounts payable
     (1,186     1,842  
Accrued expenses and other current liabilities
     (4,828     1,411  
Other liabilities
     10         (164
    
 
 
   
 
 
 
Net cash provided by (used in) operating activities
     1,411       (1,300
Cash flows from investing activities:
                
Purchases of property and equipment
     (6,672     (4,957
    
 
 
   
 
 
 
Net cash used in investing activities
     (6,672     (4,957
Cash flows from financing activities:
                
Payments of term loan
     (469         
Payments of withholding taxes in connection with RSUs vesting
     (488     (417
Proceeds from the exercise of stock options
     291       984  
Principal repayments of finance lease obligations
     (99     (675
Payment of deferred acquisition consideration
              (483
    
 
 
   
 
 
 
Net cash used in financing activities
     (765     (591
Change in cash
, cash equivalents,
and restricted cash
     (6,026     (6,848
Cash
, cash equivalents,
and restricted cash, beginning of period
     114,528       84,806  
    
 
 
   
 
 
 
Cash
, cash equivalents,
and restricted cash, end of period
   $ 108,502     $ 77,958  
    
 
 
   
 
 
 
Supplemental disclosure of cash flow information:
                
Cash paid for interest
   $ 627     $ 1,937  
Cash paid for income taxes
   $ 4     $     
Supplemental disclosure of
non-cash
investing and financing activities:
                
Purchases of property and equipment included in accounts payable and accrued expenses
   $ 1,869     $ 306  
Right-of-use
assets obtained through operating lease obligations
   $ 171     $ 310  
The accompanying notes are an integral part of these unaudited consolidated financial statements.
 
7

ORGANOGENESIS HOLDINGS INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data)
1. Nature of Business and Basis of Presentation
Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp.) (“ORGO” or the “Company”) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Several of the existing and pipeline products in the Company’s portfolio have Premarket Application (“PMA”) approval, or Premarket Notification 510(k) clearance from the United States Food and Drug Administration (“FDA”). The Company’s customers include hospitals, wound care centers, government facilities, ambulatory service centers (“ASCs”) and physician offices. The Company has one operating and reportable segment.
COVID-19
pandemic
The coronavirus
(COVID-19)
pandemic around the world, and particularly in the United States, continues to present risks to the Company. While the
COVID-19
pandemic has not materially adversely affected the Company’s financial results and business operations through March 31, 2022, the Company is unable to predict the impact that
COVID-19
will have on its financial position and operating results because of the numerous uncertainties created by the unprecedented nature of the pandemic.
The Company is closely monitoring the evolving impact of the pandemic on all aspects of its business. The Company has implemented a number of measures designed to protect the health and safety of its employees, support its customers and promote business continuity.
2. Summary of Significant Accounting Policies
The Company’s significant accounting policies are described in Note “2. Significant Accounting Policies” to the Consolidated Financial Statements included in the Company’s Annual Report on Form
10-K
for the fiscal year ended December 31, 2021, as amended (the “Annual Report”). There have been no material changes to the significant accounting policies previously disclosed in the Annual Report.
Unaudited Interim Financial Information
The accompanying unaudited consolidated financial statements have been prepared by management in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited quarterly financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report.                
The unaudited consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc. and its wholly-owned subsidiaries of Organogenesis Inc., including Organogenesis GmbH (a Switzerland corporation) and Prime Merger Sub, LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations and cash flows at the dates and for the periods indicated. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include: revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets); assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs; and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions.
 
8

Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”)
No. 2019-12,
Income Taxes— Simplifying the Accounting for Income Taxes
. The standard intends to simplify and reduce the cost of accounting for income taxes. The new guidance removes certain exceptions for recognizing deferred taxes for foreign investments, the incremental approach to performing intraperiod allocation, and calculating income taxes in interim periods for year to date losses that exceed anticipated full year losses. The standard also adds guidance to reduce complexity in certain areas, including accounting for franchise taxes that are partially based on income, transactions with a government that result with a step up in the tax basis of goodwill, changes in tax law enacted during interim periods, and allocating taxes to members of a consolidated group which are not subject to tax. For public business entities, the amendments in ASU
2019-12
are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for all periods in which financial statements have not yet been issued, including interim periods. The Company adopted this standard on January 1, 2021 and noted no impact to the financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
In June 2016, the FASB issued
ASU 2016-13
, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
 (“ASU 2016-13”). Subsequent
to the issuance of
ASU 2016-13, the
FASB has issued the following updates:
ASU 2018-19,
 Codification Improvements to Topic 326, Financial Instruments- Credit Losses
,
ASU 2019-04,
 Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments
,
ASU 2019-05,
 Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief
 and
ASU 2019-11,
 Codification Improvements to Topic 326, Financial Instruments—Credit Losses
. The objective of
ASU 2016-13 and
all the related updates is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments in this ASU replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.
ASU 2016-13 and
the related updates are effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities excluding entities eligible to be smaller reporting companies and for fiscal years, and interim periods within those years, beginning after December 15, 2022 for all other entities. Early adoption is permitted. As the Company was a smaller reporting company when the standard was issued, the Company took advantage of the extended transition period and will adopt this standard and the related improvements on January 1, 2023 by recognizing a cumulative-effect adjustment to retained earnings for any impact. The Company is currently assessing the adoption of
ASU 2016-13
and the related impact on the Company’s consolidated financial statements.
In March 2020, the FASB issued ASU
No. 2020-04,
Reference Rate Reform
 (Topic 848): Facilitation of the Effects of
 Reference Rate Reform
 on Financial Reporting
 (“ASU
2020-04”).
ASU
2020-04
provides temporary optional expedients and exceptions to the US GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. In January 2021, the FASB issued ASU
No. 2021-01,
Reference Rate Reform
 (Topic 848): Scope
 (“ASU
2021-01”),
to clarify certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting to apply to derivatives that are affected by the discounting transition. Both ASU
2020-04
and ASU
2021-01
are effective upon issuance through December 31, 2022. The Company’s debt agreement that utilizes LIBOR has conventional LIBOR replacement language. Since the debt agreement has not discontinued the use of LIBOR, this ASU is not yet effective for the Company. To the extent the interest rate changes to the rate specified in the debt agreement, the Company will utilize the relief in this ASU. The Company evaluated the effects of adopting the provisions of ASU
2020-04
and ASU
2021-01
and does not expect a material impact on the Company’s consolidated financial statements.
 
3. Acquisition
On September 17, 2020 (the “Acquisition Date”), the Company acquired certain assets and assumed certain liabilities of CPN Biosciences, LLC (“CPN”) pursuant to an asset purchase agreement dated July 24, 2020. CPN offered a physician office management solution and advanced wound care products.
The aggregate consideration amounted to $19,024 as of the Acquisition Date, consisting of $6,427 in cash, 2,151,438 shares of the Company’s Class A common stock with a fair value of $8,815, and contingent consideration (the “Earnout”) with a fair value of $3,782. On the Acquisition Date, the Company paid $5,820 in cash and issued 1,947,953 shares of the Company’s Class A common stock. The remaining consideration of $1,436 was held back and was released in April 2022 by the Company paying additional $739 in cash and issuing additional 203,485 shares of the Company’s Class A common stock to the former
equityholders
of CPN.
9

The Company is obligated to pay the Earnout to CPN’s former
equityholders
if CPN’s legacy product revenue in the Earnout Period (July 1, 2021 to June 30, 2022), exceeds CPN’s 2019 revenue. The amount of the Earnout, if any, will be equal to 70% of the excess and will be payable 60 days after the expiration of the Earnout Period. The Company recorded a
non-current
liability of $3,782 on the Acquisition Date for the fair value of the contingent consideration related to the expected Earnout. The Company assesses the fair value of the Earnout liability at each reporting period. As of March 31, 2022, the Earnout liability was estimated at $0 as a result of the Company’s updated assessment of the near-term market for the CPN product portfolio. Subsequent changes in the estimated fair value of the liability are reflected in earnings until the liability is settled. See Note “5. Fair Value Measurement of Financial
Assets and Liabilities”.
4. Product and Geographic Sales
The Company generates revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single performance obligation in all of the Company’s contracts, which is the Company’s promise to transfer the Company’s products to customers based on specific payment and shipping terms in the arrangement. The entire transaction price reflects a single performance obligation. Product revenue is recognized when a customer obtains control of the Company’s products which occurs at a point in time and may be upon shipment, procedure date, or delivery, based on the terms of the contract. Revenue is recorded net of a reserve for returns, discounts
,
and Group Purchasing Organization (“GPO”) rebates, which represent a direct reduction to the revenue recognized. These reductions are accrued at the time revenue is recognized, based upon historical experience and specific circumstances. For the three months ended March 31, 2022 and 2021, the Company recorded GPO fees of $619 and $700, respectively, as a direct reduction of revenue.
The following tables set forth revenue by product category:
 
 
  
Three Months Ended

March 31,
 
 
  
2022
 
  
2021
 
Advanced Wound Care
   $ 90,950      $ 90,708  
Surgical & Sports Medicine
     7,167        11,844  
    
 
 
    
 
 
 
Total net revenue
   $ 98,117      $ 102,552  
    
 
 
    
 
 
 
For all periods presented, net revenue generated outside the United States represented less than 1% of total net revenue.
5. Fair Value
Measurement
 
of Financial Assets and Liabilities
As of March 31, 2022 and December 31, 2021, the Company’s financial assets and liabilities measured at fair value on a recurring basis only included the Earnout liability as discussed below.
Earnout Liability
In connection with accounting for the CPN acquisition on September 17, 2020, the Company recorded an Earnout liability of $3,782 on the Acquisition Date, representing the fair value of contingent consideration payable upon the achievement of a certain revenue target. The Earnout liability is classified as a Level 3 measurement within the fair value hierarchy for which fair value is derived from inputs that are unobservable and significant to the overall fair value measurement. The fair value of such Earnout liability is estimated using a Monte Carlo simulation model that utilizes key assumptions including forecasted revenues and volatilities of the underlying financial metrics during the Earnout Period. The Company assesses the fair value of the Earnout liability at each reporting period. Any subsequent changes in the estimated fair value of the liability are reflected in selling, general and administrative expenses until the liability is settled. For more information about the Earnout liability, refer to Note “3. Acquisition”. As of December 31, 2021 and March 31, 2022, the Earnout liability was $0 as a result of the Company’s updated assessment of the near-term market for the CPN product portfolio. The following table provides a roll-forward of the fair value of the Company’s Earnout liability, for which fair value is determined using Level 3
inputs: 
 
 
  
Three Months Ended

March 31,
 
 
  
2022
 
  
2021
 
Beginning balance
   $         $ 3,985  
Change in fair value
               (296
    
 
 
    
 
 
 
Ending balance
   $         $ 3,689  
    
 
 
    
 
 
 

10

The Company did not have any financial assets a
nd
liabilities measured at fair value on a
non-recurring
basis as of March 31, 2022 or December 31, 2021.
6. Accounts Receivable, Net
Accounts receivable consisted of the following:
 
 
  
March 31
 
  
December 31,
 
 
  
2022
 
  
2021
 
Accounts receivable
   $ 84,604      $ 87,613  
Less — allowance for doubtful accounts
     (5,127      (5,153
    
 
 
    
 
 
 
     $ 79,477      $ 82,460  
    
 
 
    
 
 
 
 
The Company’s allowance for doubtful accounts was comprised of the following: 
 
                
                
 
  
Three Months Ended

March 31,
 
 
  
2022
 
  
2021
 
Balance at beginning of period
   $ 5,153      $ 2,669  
Additions 
     40        921  
Write-offs
     (66      (14
    
 
 
    
 
 
 
Balance at end of period
   $ 5,127      $ 3,576  
    
 
 
    
 
 
 
7. Inventories
Inventories, net of related reserves for excess and obsolescence, consisted of the following:
 
 
  
March 31,
 
  
December 31,
 
 
  
2022
 
  
2021
 
Raw materials
   $ 9,524      $ 9,023  
Work in process
     995        991  
Finished goods
     12,218        15,008  
    
 
 
    
 
 
 
     $ 22,737      $ 25,022  
    
 
 
    
 
 
 
Raw materials include various components used in the Company’s manufacturing process. The Company’s excess and obsolete inventory review process includes analysis of sales forecasts and historical sales as compared to inventory level and working with operations to maximize recovery of excess inventory. During the three months ended March 31, 2022 and 2021, the Company charged $2,205 and $2,290, respectively, for inventory excess and obsolescence to cost of goods sold within the consolidated statements of operations.
8. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following:
 
 
  
March 31,

2022
 
  
December 31,

2021
 
Subscriptions
   $ 2,685      $ 2,745  
Conferences and marketing expenses
     2,060        538  
Deposits
     1,344        1,216  
Insurance
     1,001        358  
Other
     45        112  
    
 
 
    
 
 
 
     $ 7,135      $ 4,969  
    
 
 
    
 
 
 
Deposits are funds held by vendors which are expected to be released within twelve months and therefore they are recorded as current assets.

11

9. Property and Equipment, Net
Property and equipment consisted of the following: 
 
 
  
March 31,
2022
 
  
December 31,
2021
 
Leasehold improvements
   $ 33,973      $ 30,531  
Buildings
     4,943        4,943  
Furniture, computers and equipment
     54,822        53,959  
    
 
 
    
 
 
 
       93,738        89,433  
Accumulated depreciation and amortization
     (59,075      (57,729
Construction in progress
     49,605        47,456  
    
 
 
    
 
 
 
     $ 84,268      $ 79,160  
    
 
 
    
 
 
 
Depreciation expense was $1,347 and $1,010, for the three months ended March 31, 2022 and 2021, respectively.
Construction in progress primarily represents unfinished c
ons
truction work on a purchased building located on the Company’s Canton, Massachusetts campus and improvements at the Company’s leased facilities in Canton and Norwood, Massachusetts.
10. Goodwill and Intangible Assets
Goodwill was $28,772 as of March 31, 2022 and December 31, 2021.
Identifiable intangible assets consisted of the following as of March 31, 2022: 
 
 
  
Original
Cost
 
  
Accumulated
Amortization
 
  
Net Book
Value
 
Developed technology
   $ 32,620      $ (18,573    $ 14,047  
Trade names and trademarks
     2,080        (1,236      844  
Customer relationships
     10,690        (1,648      9,042  
Independent sales agency network
     4,500        (4,500      —    
Patent
     7,623        (7,623      —    
Non-compete
agreements
     1,010        (491      519  
    
 
 
    
 
 
    
 
 
 
Total
   $ 58,523      $ (34,071    $ 24,452  
    
 
 
    
 
 
    
 
 
 
Identifiable intangible assets consisted of the following as of December 31, 2021: 
 
 
  
Original
Cost
 
  
Accumulated
Amortization
 
  
Net Book
Value
 
Developed technology
   $ 32,620      $ (17,709    $ 14,911  
Trade names and trademarks
     2,080        (1,183      897  
Customer relationship
     10,690        (1,381      9,309  
Independent sales agency network
     4,500        (4,500      —    
Patent
     7,623        (7,623      —    
Non-compete
agreements
     1,010        (454      556  
    
 
 
    
 
 
    
 
 
 
Total
   $ 58,523      $ (32,850    $ 25,673  
    
 
 
    
 
 
    
 
 
 
Amortization of intangible assets, calculated on a straight-line basis or using an accelerated method, was $1,221 and $1,243 for the three months ended March 31, 2022 and 2021, respectively.

12

11. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following: 
 
 
  
March 31,
2022
 
  
December 31,
2021
 
Personnel costs
   $ 23,060      $ 26,865  
Royalties
     3,190        3,458  
Accrued but unpaid lease obligations and interest
     3,981        3,963  
Other
     2,188        2,303  
    
 
 
    
 
 
 
     $ 32,419      $ 36,589  
    
 
 
    
 
 
 
The accrued but unpaid lease obligations and the interest accrual on these obligations are related to the buildings in Canton, Massachusetts. See Note “17. Leases”.
12. Restructuring
In order to reduce the Company’s cost structure and achieve operating efficiency, the Company is consolidating its manufacturing operations in various locations into Massachusetts facilities.
On October 21, 2020, the Company committed to a plan to restructure the workforce and operations in its La Jolla, California facilities. The restructuring involved approximately 
65 employees and was substantially completed as of December 31, 2021, with certain facility and storage activities continuing through 2024.
 
On March 9, 2022, the Company committed
to
a plan to restructure the workforce and operations in its Birmingham facilities. The restructuring is expected to be completed by the end of 2022 and will result in a charge of approximately
 $3.0 million, of which approximately $2.0 million is attributable to the retention benefits associated with approximately 25 employees and the remaining $1.0 
million is related to the other exit activities, including but not limited to contract termination, decommission and transportation of certain fixed assets. As employees are required to provide future services, employee retention and other benefit-related costs are expensed over the service period.
As a result of the restructuring activities, the Company incurred
a pre-tax charge
of $264 and $927 during the three months ended March 31, 2022 and 2021, respectively. These charges were included in selling, general and administrative expenses in the consolidated statements of operations. The liability related to the restructuring activities was $132 and $3,168 as of March 31, 2022 and December 31, 2021, respectively, and was included in accrued expenses and other current liabilities in the consolidated balance sheets. The following table provides a roll-forward of the restructuring liability. 
 
 
  
Employee
 
  
Other
 
  
Total
 
Liability balance as of December 31, 2021
   $ 2,517      $ 651  

$
 
3,168
 
Expenses
     115        149  
 
 
264
 
Payments
     (2,517      (783
 
 
(3,300
)

    
 
 
    
 
 
 
 
 
 
 
Liability balance as of March 31, 2022
   $ 115      $ 17  
 
$
132
 
    
 
 
    
 
 
 
 
 
 
 
13. Long-Term Debt Obligations
Long-term debt obligations consisted of the following: 
 
 
  
March 31,
2022
 
  
December 31,
2021
 
Line of credit
   $         $     
    
 
 
    
 
 
 
Term loan
     73,593        74,062  
Less debt discount and debt issuance cost
     (598      (637
    
 
 
    
 
 
 
Term loan, net of debt discount, debt issuance cost
   $ 72,995      $ 73,425  
    
 
 
    
 
 
 
13

2021 Credit Agreement
In August 2021, the Company, as borrower, its subsidiaries, as guarantors, and Silicon Valley Bank (“SVB”), and the several other lenders thereto (collectively, the “Lenders”) entered into a credit agreement (the “2021 Credit Agreement”), providing for a term loan facility not to exceed $75,000 (the “Term Loan Facility”) and a revolving credit facility not to exceed $125,000 (the “Revolving Facility”). The Company’s obligations to the Lenders are secured by substantially all of the Company’s assets, including intellectual property. Capitalized terms used herein and not otherwise defined are defined as set forth in the 2021 Credit Agreement.
Advances
made under the 2021 Credit Agreement may be either Eurodollar Loans or ABR Loans, at the Company’s option. For Eurodollar Loans, the interest rate is a per annum interest rate equal to LIBOR plus an Applicable Margin between 2.00% to 3.25% based on the Total Net Leverage Ratio. For ABR Loans, the interest rate is equal to (1) the highest of (a) the Wall Street Journal Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) the LIBOR rate plus 1.0%,
plus
(2) an Applicable Margin between 1.00% to 2.25% based on the Total Net Leverage Ratio.
The 2021 Credit Agreement requires the Company to make consecutive quarterly installment payments equal to the following: (a) from September 30, 2021 through and including June 30, 2022, $469; (b) from September 30, 2022 through and including June 30, 2023, $938; (c) from September 30, 2023 through and including June 30, 2025, $1,406 and (d) from September 30, 2025 and the last day of each quarter thereafter until August 6, 2026 (the “Term Loan Maturity Date”), $1,875. The Company may prepay the Term Loan Facility, provided that any Term Loans prepaid prior to August 6, 2022 must be accompanied by a prepayment premium equal to 1.00% of the aggregate amount of Term Loans prepaid. Once repaid, amounts borrowed under the Term Loan Facility may not
be re-borrowed.
The Company must pay in arrears, on the first day of each quarter prior to August 6, 2026 (the “Revolving Termination Date”) and on the Revolving Termination Date, a fee for the
Company’s non-use of
available funds (the “Commitment Fee”). The Commitment Fee rate is between 0.25% to 0.45% based on the Total Net Leverage Ratio. The Company may elect to reduce or terminate the Revolving Facility in its entirety at any time by repaying all outstanding principal, unpaid accrued interest and, with respect to any such reduction or termination of the Revolving Commitments made prior to August 6, 2022, 1.00% of the aggregate amount of the Revolving Commitments so reduced or terminated.
 
Under the 2021 Credit Agreement, the Company is required to comply with certain financial covenants including the Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio, tested quarterly. In addition, the Company is also required to make representations and warranties and comply with certain
non-financial
covenants that are customary in loan agreements of this type, including restrictions on the payment of dividends, repurchase of stock, incurrence of indebtedness, dispositions and acquisitions.
The Company had outstanding borrowings of $73,593 and $74,062 under the Term Loan Facility and $0 under the Revolving Facility with $125,000 available for future revolving borrowings as of March 31, 2022 and December 31, 2021, respectively. The Company recorded additional debt issuance costs and related fees of $604 in connection with the Term Loan Facility, which are recorded as a reduction of the carrying value of the term loan on the Company’s consolidated balance sheets. In connection with the Revolving Facility, the Company recorded debt issuance costs and related fees of $1,223, which are recorded as other assets. Both of these costs are being amortized to interest expense through the maturity date of the facilities.
Future payments of the 2021 Credit Agreement, as of March 31, 2022, are as follows for the calendar years ending December 31:
 
2022
   $ 2,343  
2023
     4,687  
2024
     5,625  
2025
     6,563  
2026
     54,375  
    
 
 
 
Total
   $ 73,593  
    
 
 
 
2019 Credit Agreement
In March 2019, the Company, its subsidiaries and SVB, and the several other lenders thereto entered into a credit agreement, as amended (the “2019 Credit Agreement”), providing for a term loan facility of $40,000 and a revolving credit facility of up to $60,000. Both facilities were set to mature in 2024. The interest rate for the term loan facility was a floating per annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%. The interest rate for advances under the revolving facility was a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50%. If the Company elected to prepay the loan or terminate the facilities, the Company was required to pay a certain percentage of the outstanding principal as a prepayment fee. A final payment fee (the “Final Payment”) of 6.5% multiplied by the original aggregate principal amount of term loan facility was due upon the earlier to occur of the maturity date of the term loan or prepayment of all outstanding principal
.

 
 
14

In August 2021, upon entering into the 2021 Credit Agreement, the Company paid an aggregate amount of $70,559 due under the 2019 Credit Agreement, including unpaid principal, accrued interest, the Final Payment and a prepayment fee, with proceeds from the 2021 Credit Agreement, and the 2019 Credit Agreement was terminated. Upon termination of the 2019 Credit Agreement, the Company recognized $1,883 as loss on the extinguishment of the loan for the year ended December 31, 2021.
14. Stockholders’ Equity
Common Stock
As of March 31, 2022,
t
he issued shares of Class A common stock include 728,548 treasury shares that were reacquired in connection with the redemption of redeemable shares in March 2019.
As of March 31, 2022 and December 31, 2021, the Company reserved the following shares of Class A common stock for future issuance:
 
 
  
March 31
2022
 
  
December 31,
2021
 
Shares reserved for issuance for outstanding options
     7,924,792        6,596,969  
Shares reserved for issuance for outstanding restricted stock units
     1,496,853        764,871  
Shares reserved for issuance for future grants
     3,373,334        5,644,691  
    
 
 
    
 
 
 
Total shares of authorized common stock reserved for future issuance
     12,794,979        13,006,531  
    
 
 
    
 
 
 
 
15. Stock-Based Compensation
Stock Incentive
Plans-the
2018 Plan
On November 28, 2018, the Board of Directors of the Company adopted, and on December 10, 2018 the Company’s stockholders approved, the Organogenesis 2018 Equity and Incentive Plan (the “2018 Plan”). The purposes of the 2018 Plan are to provide long-term incentives and rewards to the Company’s employees, officers, directors and other key persons (including consultants), to attract and retain persons with the requisite experience and ability, and to more closely align the interests of such employees, officers, directors and other key persons with the interests of the Company’s stockholders.
The 2018 Plan authorizes the Company’s Board of Directors or a committee of not less than two independent directors (in either case, the “Administrator”) to grant the following types of awards:
non-statutory
stock options; incentive stock options; restricted stock awards; restricted stock units; stock appreciation rights; unrestricted stock awards; performance share awards; and dividend equivalent rights. The 2018 Plan is administered by the Company’s Board of Directors.
A total of
 9,198,996
shares of Class A common stock have been authorized to be issued under the 2018 Plan (subject to adjustment in the case of any stock dividend, stock split, reverse stock split, or similar change in capitalization of the Company). There has been no change to the total authorized shares since the adoption of the 2018 Plan.
Stock Incentive
Plans-the
2003 Plan
The Organogenesis 2003 Stock Incentive Plan (the “2003 Plan”), provides for the Company to issue restricted stock awards, or to grant incentive stock options or
non-statutory
stock options. Incentive stock options may be granted only to the Company’s employees. Restricted stock awards and
non-statutory
stock options may be granted to employees, members of the Board of Directors, outside advisors and consultants of the Company.
Effective as of the closing of the Avista Merger on December 10, 2018, no additional awards may be made under the 2003 Plan and as a result (i) any shares in respect of stock options that are expired or terminated under the 2003 Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares of Class A common stock that are tendered to the Company by a participant to exercise an award will not be available for future awards.
Stock-Based Compensation Expense
Stock options awarded under the stock incentive plans expire 10 years after the grant date and typically vest over four or five years. Restricted stock units awarded typically vest over four years.
 
15

Stock-based compensation expense was $1,303 and $698 for the three months ended March 31, 2022 and 2021, respectively. The total amount of stock-based compensation expense was included within selling, general and administrative expenses on the consolidated statements of operations.
Restricted Stock Units (RSUs)
The Company granted 931,431 and 284,708 time-based restricted stock units to its employees, executives and the Board of Directors in the three months ended March 31, 2022 and 2021, respectively. Each restricted stock unit represents the contingent right to receive one share of the Company’s Class A common stock. A majority of the restricted stock units will vest in four equal annual installments. The fair value of the restricted stock units was based on the fair market value of the Company’s stock on the date of grant.
The activity of restricted stock units is set forth below: 
 
 
  
Number of
Shares
 
  
Weighted
Average
Grant Date
Fair Value
 
Unvested at December 31, 2021
     764,871      $ 7.52  
Granted
     931,431        7.59  
Vested
     (179,714      7.81  
Canceled/Forfeited
     (19,735      6.83  
    
 
 
    
 
 
 
Unvested at March 31, 2022
     1,496,853      $     7.54  
    
 
 
    
 
 
 
As of March 31, 2022, the total unrecognized compensation cost related to unvested restricted stock units expected to vest was $7,892 and the weighted average remaining recognition period for unvested awards was 3.19 years.
Stock Option Valuation
The stock options granted during the three months ended March 31, 2022 and 2021 were 1,418,224 and 1,037,099, respectively. The assumptions that the Company used to determine the grant-date fair value of stock options granted during these periods were as follows, presented on a weighted-average basis:
                 
    
Three Months Ended

March 31,
 
    
2022
   
2021
 
Risk-free interest rate
     1.92     0.82
Expected term (in years)
     6.25       6.21  
Expected volatility
     50.66     39.30
Expected dividend yield
     0.0     0.0
Exercise price
   $ 8.03     $ 13.54  
Underlying stock price
   $     7.87     $     13.54  

16

These assumptions resulted in an estimated weighted-average grant-date fair value per share of stock options granted during the three months ended March 31, 2022 and 2021 of $3.94 and $5.31, respectively.
Stock Option Activity
The following table summarizes the Company’s stock option activity since December 31, 2021: 
 
 
  
Number of
Shares
 
  
Weighted
Average
Exercise
Price
 
  
Weighted
Average
Remaining
Contractual
Term

(in years)
 
  
Aggregate
Intrinsic
Value
 
Outstanding as of December 31, 2021
     6,596,969      $ 4.10        5.20      $ 38,524  
Granted
     1,418,224        8.03                    
Exercised
     (86,121      3.38                 441  
Canceled / forfeited
     (4,280      2.69                    
    
 
 
                            
Outstanding as of March 31, 2022
     7,924,792        4.82        5.83        29,053  
    
 
 
                            
Options exercisable as of March 31, 2022
     4,600,567        2.52        3.57        25,113  
    
 
 
                            
Options vested or expected to vest as of March 31, 2022
     7,215,073      $ 4.44        5.50      $ 28,567  
    
 
 
                            
The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those stock options that have exercise prices lower than the fair value of the Company’s Class A common stock.
The total fair value of options vested during the three months ended March 31, 2022 and 2021 was $1,612 and $143, respectively.
As of March 31, 2022, the total unrecognized stock compensation expense related to unvested stock options expected to vest was $7,579 and was expected to be recognized over a weighted-average period of 3.29 years.
16. Net Income per Share (EPS)
Basic EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding during the period. Diluted EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding plus the dilutive effect, if any, of outstanding equity awards using the treasury stock method which includes consideration of unrecognized compensation expenses as additional proceeds.
 
A reconciliation of the numerator and denomina
to
r used in the calculation of the basic and diluted net income attributable to the Class A common stockholders is as follows.
 
 
  
Three Months Ended
March 31,
 
 
  
2022
 
  
2021
 
Numerator:
                 
Net Income
   $ 87      $ 9,943  
Denominator:
                 
Weighted average common shares outstanding —basic

     128,788,721        127,870,065  
Dilutive effect of restricted stock units
     264,075        527,658  
Dilutive effect of options
     3,752,358        5,054,227  
    
 
 
    
 
 
 
Weighted-average common shares outstanding—diluted
     132,805,154        133,451,950  
Earnings per share—basic
   $ 0.00      $ 0.08  
    
 
 
    
 
 
 
Earnings per share—diluted
   $ 0.00      $ 0.07  
    
 
 
    
 
 
 

17

For the three months ended March 31, 2022 and
20
21, outstanding stock-based awards of 155,207 and 1,202,193 were excluded from the diluted EPS calculation as they were anti-dilutive.
17. Leases
As of December 31, 2021 and March 31, 2022, the Company’s contracts that contained a lease consisted primarily of real estate, equipment and vehicle leases.
The Company leases real estate for office, lab, warehouse and production space under noncancelable leases that expire at various dates through 2035, subject to the Company’s options to terminate or renew certain leases for an additional five to ten years.
The Company leases vehicles under operating leases for certain employees and has fleet services agreements for service on these vehicles. The minimum lease term for each newly leased vehicle is 367 days with renewal options. The Company may terminate the vehicle lease after the minimum lease term upon thirty days’ prior notice.
The Company also leases other equipment under noncancelable operating and finance leases that expire at various dates through 2025.
The Company determines if an arrangement is a lease at lease inception. The options to extend or terminate a lease are included in the lease terms when it is reasonably certain that the Company will exercise the options. Operating leases are included in operating lease
right-of-use
assets and operating lease obligations on the consolidated balance sheets. Finance lease
right-of-use
assets are included in property and equipment, net, and the related liabilities are included in finance lease obligations on the consolidated balance sheets.
Right-of-use
assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the leases.
Right-of-use
assets and lease liabilities are recognized based on the present value of the fixed lease payments over the lease term at the commencement date. The
right-of-use
assets also include any initial direct costs incurred and lease payments made at or before the commencement date and are reduced by lease incentives. The Company uses its incremental borrowing rate as the discount rate to determine the present value of the lease payments for leases that do not have a readily determinable implicit discount rate. The Company’s incremental borrowing rate is the rate of interest that it would have to borrow on a collateralized basis over a similar term and amount in a similar economic environment. The Company determines the incremental borrowing rates for its leases by adjusting the risk-free interest rate with a credit risk premium corresponding to the Company’s credit rating.
The Company records rent expense for its operating leases on a straight-line basis from the lease commencement date until the end of the lease term. The Company records finance lease cost as a combination of the depreciation expense for the
right-of-use
assets and interest expense for the outstanding lease liabilities using the discount rate discussed above. Variable lease payments are primarily related to the office and fleet leases which include but are not limited to taxes, insurance, common area maintenance and maintenance programs for leased vehicles. Variable lease payments are based on the occurrence or usage; therefore, they are not included as part of the initial
right-of-use
assets and liabilities calculation.

On January 1, 2013, the Company entered into finance lease arrangements with 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC for office and laboratory space in Canton, Massachusetts. 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC are related parties as the owners of these entities are also stockholders of the Company. Other than the lease with 275 Dan Road SPE, LLC which was terminated in August 2021 as discussed below, the remaining three leases were set to terminate on December 31, 2022 and each contained a renewal option for a five-year period with a rental rate at the greater of (i) rent for the last year of the prior term, or (ii) the then fair market value. The Company exercised the option to extend the leases for an additional five years in November 2021. These leases were reclassified from finance leases to operating leases upon the Company’s reassessment of the lease classification according to ASC
842-10-25-1
Lease Classification.
The related finance lease assets and liabilities were reclassified to operating
lease right-of-use assets
and operating lease obligations on the consolidated balance sheet as of December 31, 2021.
As of December 31, 2020, the Company owed an aggregate of $10,336 of accrued but unpaid lease obligations under the aforementioned leases. Effective April 1, 2019, the Company agreed to accrue interest on the accrued but unpaid lease obligations at an interest rate equal to the rate charged in the 2019 Credit Agreement. These accrued but unpaid lease obligations as well as the accrued interest on these obligations were subordinated to the 2019 Credit Agreement. With the termination of the 2019 Credit Agreement and the execution of the 2021 Credit Agreement (see Note “13. Long-Term Debt Obligations”) in August 2021, these obligations are no longer subordinated to the Company’s existing loans.
 
18

In
August 2021, the Company purchased the building (the “275 Dan Road Building”) under the lease with 275 Dan Road SPE, LLC for $6,013 and the lease was terminated. The Company recorded an asset of $4,943 to buildings within fixed asset, net in accordance with ASC
842-20-40-2
Purchase of the Underlying Asset
to account for the purchase of the leased asset. In connection with the purchase of the 275 Dan Road Building, the Company paid 50% of the accrued but unpaid lease obligations associated with this building and the accrued interest thereof. The remaining balance is being paid in five quarterly installments ending on January 3, 2023. The interest on the balance of the accrued but unpaid lease obligations associated with the 275 Dan Road Building was reduced to an annual simple rate of 4.5%.
The accrued but unpaid lease obligations as well as the related interest accruals are shown below.
 
 
  
March 31
 
  
December 31,
 
 
  
2022
 
  
2021
 
Principal portion of rent in arrears
     7,246        7,246  
Unpaid operating and common area maintenance costs
     52        558  
    
 
 
    
 
 
 
Total accrued but unpaid lease obligations
     7,298        7,804  
Accrued interest on accrued but unpaid lease obligations
     1,956        1,938  
The principal portion of rent in arrears was included in the short-term portion of operating lease obligations other than the balance related to the 275 Dan Road Building that was included in accrued expenses and other current liabilities on the consolidated balance sheets as of March 31, 2022 and December 31, 2021. The unpaid operating and common area maintenance costs, and the accrued interest on the accrued but unpaid lease obligations were included in accrued expenses and other current liabilities on the consolidated balance sheets as of March 31, 2022 and December 31, 2021
.
 
The components of lease cost were as follows:
 
 
  
 
  
Three Months Ended

March 31,
 
  
Classification
  
 
2022
 
  
 
2021
 
  
  
 
 
 
  
 
 
 
Finance lease
  
  
  
Amortization of
right-of-use
assets
   COGS and SG&A    $ 107      $ 299  
Interest on lease liabilities
   Interest Expense      5        349  
         
 
 
    
 
 
 
Total Finance lease cost
          112        648  
Operating lease cost
   COGS, R&D, SG&A      2,434        1,280  
Short-term lease cost
   COGS, R&D, SG&A     
669
       715  
Variable lease cost
   COGS, R&D, SG&A     
918
       1,363  
         
 
 
    
 
 
 
Total lease cost
        $ 4,133      $ 4,006  
         
 
 
    
 
 
 
Supplemental balance sheet information related to finance leases was as follows:
 
 
  
March 31, 2022
 
  
December 31,
2021
 
Property and equipment, gross
   $ 1,174      $ 1,174  
Accumulated depreciation
     (1,067      (961
    
 
 
    
 
 
 
Property and equipment, net
   $ 107      $ 213  
    
 
 
    
 
 
 
Finance lease obligations

  
$

101
    
$

200

 
    
 
 
    
 
 
 

19

Supplemental cash flow information related to leases was as follows:
 
                    
                    
 
  
Three Months Ended

March 31,
 
 
  
2022
 
  
2021
 
Cash paid for amounts included in the measurement of lease liabilities:
  
  
Operating cash flows for operating leases
   $ 2,337      $ 1,362  
Operating cash flows for finance leases
   $ 5      $ 523  
Financing cash flows for finance leases
   $ 99      $ 675  
Right-of-use
assets obtained in exchange for lease obligations
                 
Operating leases
   $ 171      $ 310  
Finance leases
   $ —        $ —    
 
 
  
March 31,
2022
 
 
December 31,
2021
 
Weighted-average remaining lease term
  
 
Finance leases
     0.21        0.45  
Operating leases
     8.04        8.22  
 
  
March 31,
2022
 
 
December 31,
2021
 
Weighted-average discount rate
  
 
Finance leases
     11.30     11.30
Operating leases
     4.53     4.51
As of March 31, 2021, maturities of lease liabilities were as follows:
                 
    
Operating leases
    
Finance leases
 
2022
   $ 11,873      $ 103  
2023
     8,104            
2024
     7,315            
2025
     7,526            
2026
     7,435            
Thereafter
     25,966            
    
 
 
    
 
 
 
Total lease payments
     68,219        103  
Less: interest
     (11,121      (2
    
 
 
    
 
 
 
Total lease liabilities
   $     57,098      $     101  
    
 
 
    
 
 
 
18. Commitments and Contingencies
Royalties
The Company entered into a license agreement with a university for certain patent rights related to the development, use and production of one of its advanced wound care products. Under this agreement, the Company incurred a royalty based on a percentage of net product sales, for the use of these patents until the patents expired, which was in November 2006. Accrued royalties totaled $1,187 as of March 31, 2022 and December 31, 2021, respectively, and were classified as part of accrued expenses and other current liabilities on the Company’s consolidated balance sheets. There was no royalty expense incurred during the three months ended March 31, 2022 or 2021 related to this agreement.
In October 2017, the Company entered into a license agreement with a third party. Under the license agreement, the Company is required to pay royalties based on a percentage of net sales of the licensed product that occur, after December 31, 2017, through the expiration of the underlying patent in October 2026, subject to minimum royalty payment provisions. The Company recorded royalty expense of $1,601 and $1,220 during the three months ended March 31, 2022 and 2021, respectively, within selling, general and administrative expenses on the consolidated statements of operations.

20

Legal Matters
In conducting its activities, the Company, from time to time, is subject to various claims and also has claims against others. In management’s opinion, the ultimate resolution of such claims would not have a material effect on the financial position, operating results or cash flows of the Company. The Company accrues for these claims when amounts due are probable and estimable. The Company accrued $150 as of March 31, 2022 and December 31, 2021 in relation to certain pending lawsuits.
19. Related Party Transactions
Lease obligations to affiliates, including accrued but unpaid lease obligations, and purchase of an asset under a finance lease with an affiliate are further described in Note “17. Leases”.
During 2010, the Company’s Board of Directors approved a loan program that permitted the Company to make loans to three executives of the Company (the “Employer Loans”) to (i) provide them with liquidity (“Liquidity Loans”) and (ii) fund the exercise of vested stock options (“Option Loans”). Two of the executives left the Company in 2014. The Employer Loans matured with all principal and accrued interest due on the tenth anniversary of the issuance date of each subject loan. Interest on the Employer Loans was at various rates ranging from 2.30
%
 
-
3.86% per annum, compounded annually. The Employer Loans were secured by shares of the Company’s Class A common stock held by the former executives. With respect to the Liquidity Loans, the Company had no personal recourse against the borrowers beyond the pledged shares. As of December 31, 2020, Liquidity Loans and Option Loans to one former executive were outstanding with an aggregate principal balance of $100 and $334, respectively. During the three months ended March 31, 2021, this former executive paid off the outstanding principal balance of his Employer Loans and the related interest receivable. As a result, the Company recorded $179 as a recovery of the previously reserved related party receivables within selling, general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021. The $334 of the repaid principal balance of the Option Loans was recorded to equity.
 
20. Taxes
The Company is principally subject to taxation in the United States. The Company has a history of net operating losses both federally and in various states and began utilizing those losses to offset current taxable income in 2020. The Company’s wholly owned Swiss subsidiary, Organogenesis Switzerland GmbH, is subject to taxation in Switzerland and has a transfer pricing arrangement in place with Organogenesis Inc., its U.S. parent and a wholly owned subsidiary of the Company.
The income tax rate for the three months ended March 31, 2022 varied from the U.S. statutory rate of 21% primarily due to the tax adjustments related to executive compensation, other permanent tax adjustments, and discrete items. Income tax expense for the three months ended March 31, 2022 was $45, which include
d
 a discrete tax expense of $10
,
and related primarily to federal and state taxes. Income tax expense for the three months ended March 31, 2021 was 
$200, which included a discrete expense of $10, and related primarily to state and foreign taxes.
The Company examines all positive and negative evidence to estimate whether sufficient future taxable income in the U.S. will be generated to permit the use of existing deferred tax assets. In the fourth quarter of 2021, the Company released the valuation allowance recorded against its U.S. deferred tax assets. Upon reviewing the positive evidence of net operating loss utilization, cumulative profits, and forecasted taxable income, the Company believed that it was more likely than not that these United States deferred tax assets will be utilized. There are no material deferred tax assets in the other jurisdictions. On a quarterly basis, the Company reassesses the need for a valuation allowance on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. After assessing both the positive and negative evidence, including net operating loss utilization, cumulative profits, and forecasted taxable income, the Company determined that it is more likely than not the U.S. deferred assets will be realized in full. As such, the Company has not recorded a valuation allowance against its U.S. deferred tax
assets as of March 31, 2022 and December 31, 2021. 
21. Subsequent Events
The Company has evaluated subsequent events through May 10, 2022, the date on which these consolidated financial statements were issued and has determined that there were no such events to report.
 
2
1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Form
10-Q
and the financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form
10-K
for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission, or the SEC, on March 1, 2022, as amended. Please refer to our note regarding forward-looking statements on page 3 of this Form
10-Q,
which is incorporated herein by this reference.
Overview
Organogenesis is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Our products have been shown through clinical and scientific studies to support and in some cases accelerate tissue healing and improve patient outcomes. We are advancing the standard of care in each phase of the healing process through multiple breakthroughs in tissue engineering and cell therapy. Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease and smoking. We offer our differentiated products and
in-house
customer support to a wide range of health care customers including hospitals, wound care centers, government facilities, ambulatory service centers (“ASCs”) and physician offices. Our mission is to provide integrated healing solutions that substantially improve medical outcomes and the lives of patients while lowering the overall cost of care.
We offer a comprehensive portfolio of products in the markets we serve that address patient needs across the continuum of care. We have and intend to continue to generate data from clinical trials, real-world outcomes and health economics research that validate the clinical efficacy and value proposition offered by our products. Several of our existing and pipeline products in our portfolio have PMA approval or 510(k) clearance from the FDA. Given the extensive time and cost required to conduct clinical trials and receive FDA approvals, we believe that our data and regulatory approvals provide us a strong competitive advantage. Our product development expertise and multiple technology platforms provide a robust product pipeline, which we believe will drive future growth.
In the Advanced Wound Care market, we focus on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds in various treatment settings. We have a comprehensive portfolio of regenerative medicine products, capable of supporting patients from early in the wound healing process through wound closure regardless of wound type. Our Advanced Wound Care products include Apligraf for the treatment of venous leg ulcers (“VLUs”) and diabetic foot ulcers (“DFUs”); Dermagraft for the treatment of DFUs (manufacturing currently suspended pending transition to our Massachusetts based manufacturing facilities); PuraPly AM as an antimicrobial barrier for a broad variety of wound types; and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. We have a highly trained and specialized direct wound care sales force paired with comprehensive customer support services.
In the Surgical & Sports Medicine market, we focus on products that support the healing of musculoskeletal injuries, including degenerative conditions such as osteoarthritis and tendonitis. We are leveraging our regenerative medicine capabilities in this attractive, adjacent market. Our Surgical & Sports Medicine products include NuShield for surgical application in targeted soft tissue repairs; and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. We currently sell these products through independent agencies and our growing direct sales force.
 
22

Table of Contents
For the three months ended March 31, 2022, we generated $98.1 million of net revenue and $0.1 million of net income compared to $102.6 million of net revenue and $9.9 million of net income for the three months ended March 31, 2021. While we reported net income for the most recent two years, we have incurred significant losses since inception and, we may incur operating losses in the future as we expend resources as part of our efforts to grow our organization to support the planned expansion of our business. As of March 31, 2022, we had an accumulated deficit of $60.0 million. Our primary sources of capital to date have been from sales of our products, borrowings from related parties and institutional lenders and proceeds from the sale of our Class A common stock. We operate as one segment of regenerative medicine.
COVID-19
pandemic
The emergence of the coronavirus
(COVID-19)
around the world, and particularly in the United States, continues to present risks to the Company. While the
COVID-19
pandemic has not materially adversely affected our financial results and business operations through the first quarter ended March 31, 2022, we are unable to predict the impact that
COVID-19
will have on our financial position and operating results because of the numerous uncertainties created by the unprecedented nature of the pandemic. We are closely monitoring the evolving impact of the pandemic on all aspects of our business. We have implemented a number of measures designed to protect the health and safety of our employees, support our customers and promote business continuity. We continue to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance as we manage the Company through this period of uncertainty.
End of Enforcement Grace Period for ReNu and NuCel
On November 16, 2017, the FDA issued a final guidance document entitled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use”, or 361 HCT/P Guidance, which provided the FDA’s thinking on how to apply the existing regulatory criteria for regulation as a Section 361 HCT/P. The 361 HCT/P Guidance clarified the FDA’s views about the criteria that differentiate those products subject to regulation under Section 361 of the Public Health Service Act from those considered to be drugs, devices, and/or biological products subject to licensure under Section 351 and related regulations. The 361 HCT/P Guidance originally indicated that the FDA was providing
a 36-month enforcement
grace period to allow time for distributors of HCT/Ps to make any regulatory submissions and obtain any premarket approvals necessary to comply with the guidance. In July 2020, the FDA announced that the enforcement grace period would be extended until May 31, 2021 as a result of the challenges presented by
the COVID-19 public
health emergency. On April 21, 2021, the FDA reaffirmed that the enforcement grace period would end on May 31, 2021, at which time we ceased commercial distribution of ReNu and NuCel. We are continuing to conduct clinical studies of ReNu to support FDA approval of a Biologics License Application for the treatment of knee osteoarthritis and, based on favorable feasibility studies, we believe ReNu has potential as a treatment for additional osteoarthritis and tissue regeneration applications. Accordingly, we have decided to focus on clinical development of ReNu and we discontinued clinical development of NuCel.
Dermagraft
As part of our long-term plan to consolidate manufacturing operations in Massachusetts, manufacturing of Dermagraft was suspended in the fourth quarter of 2021 and sales of Dermagraft will be suspended in the second quarter of 2022. We currently plan to transition our Dermagraft manufacturing to our Massachusetts-based manufacturing facilities, which we expect will result in substantial long-term cost savings. In the period when Dermagraft is not available (possibly for a few years), we expect that customers will be willing to substitute Apligraf for Dermagraft and that the suspension of Dermagraft sales will not have a material impact on our net revenue. However, if we do not realize the expected substantial long-term cost savings or if customers are unwilling to substitute Apligraf for Dermagraft during the period in which Dermagraft is unavailable, it could have an adverse effect on our net revenue and results of operations.
Components of Our Consolidated Results of Operations
In assessing the performance of our business, we consider a variety of performance and financial measures. We believe the items discussed below provide insight into the factors that affect these key measures.
Revenue
We derive our net revenue from our portfolio of Advanced Wound Care and Surgical & Sports Medicine products. We primarily sell our Advanced Wound Care products through direct sales representatives who manage and maintain the sales relationships with hospitals, wound care centers, government facilities, ASCs and physician offices. We primarily sell our Surgical & Sports Medicine products through third party agencies. As of March 31, 2022, we had approximately 340 direct sales representatives and approximately 150 independent agencies.
 
23

Table of Contents
We recognize revenue from sales of our Advanced Wound Care and Surgical & Sports Medicine products when the customer obtains control of our product, which occurs at a point in time and may be upon procedure date, shipment, or delivery, based on the contractual terms of a contract. We record revenue net of a reserve for returns, discounts and GPO rebates, which represent a direct reduction to the revenue we recognize.
Several factors affect our reported revenue in any period, including product, payer and geographic sales mix, operational effectiveness, pricing realization, marketing and promotional efforts, the timing of orders and shipments, regulatory actions including healthcare reimbursement scenarios, competition and business acquisitions.
Cost of goods sold and gross profit
Cost of goods sold includes personnel costs, product testing costs, quality assurance costs, raw materials and product costs, manufacturing costs, and the costs associated with our manufacturing and warehouse facilities. The increases in our cost of goods sold correspond with the increases in sales units driven by the expansion of our sales force and sales territories, expansion of our product portfolio offerings, and the number of healthcare facilities that offer our products. We expect our cost of goods sold to increase due primarily to the anticipated increase in sales volumes.
Gross profit is calculated as net revenue less cost of goods sold and generally increases as revenue increases. Our gross profit is affected by product and geographic sales mix, realized pricing of our products, the efficiency of our manufacturing operations and the costs of materials used and fees charged by third-party manufacturers to produce our products. Regulatory actions, including healthcare reimbursement scenarios, which may require costly expenditures or result in pricing pressures, may decrease our gross profit.
Selling, general and administrative expenses
Selling, general and administrative expenses generally include personnel costs for sales, marketing, sales support, customer support, and general and administrative personnel, sales commissions, incentive compensation, insurance, professional fees, depreciation, amortization, bad debt expense, royalties, information systems costs and costs associated with our administrative facilities. We generally expect our selling, general and administrative expenses to continue to increase due to increased investments in market development and the geographic expansion of our sales forces as we drive for continued revenue growth.
Research and development expenses
Research and development expenses include personnel costs for our research and development personnel, expenses related to improvements in our manufacturing processes, enhancements to our currently available products, and additional investments in our product and platform development pipeline. Our research and development expenses also include expenses for clinical trials. We expense research and development costs as incurred. We generally expect that research and development expenses will increase as we continue to conduct clinical trials on new and existing products, move products through the regulatory pathway (e.g., seek BLA approval), add personnel to support product enhancements as well as to bring new products to market, and enhance our manufacturing process and procedures.
Other expense, net
Interest expense
—Interest expense consists of interest on our outstanding indebtedness, including amortization of debt discount and debt issuance costs, net of interest income recognized.
Income taxes
We account for income taxes using an asset and liability approach. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Valuation allowances are provided when necessary to reduce net deferred tax assets to an amount that is more likely than not to be realized.
In determining whether a valuation allowance for deferred tax assets is necessary, we analyze both positive and negative evidence related to the realization of deferred tax assets including projected future taxable income, recent financial results and estimates of future reversals of deferred tax assets and liabilities. In addition, we consider whether it is more likely than not that the tax position will be sustained on examination by taxing authorities based on the technical merits of the position. Based on a consideration of the factors discussed above, we have determined that our net U.S. deferred tax assets do not require a valuation allowance as of March 31, 2022 and December 31, 2021.
 
24

Table of Contents
We account for uncertainty in income taxes recognized in the consolidated financial statements by applying
a two-step process
to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is
deemed more-likely-than-not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Results of Operations
The following table sets forth, for the periods indicated, our results of operations:
 
    
Three Months Ended

March 31,
 
    
2022
    
2021
 
Net revenue
   $ 98,117      $ 102,552  
Cost of goods sold
     25,080        25,495  
  
 
 
    
 
 
 
Gross profit
     73,037        77,057  
Operating expenses:
     
Selling, general and administrative
     63,578        58,232  
Research and development
     8,587        6,209  
  
 
 
    
 
 
 
Total operating expenses
     72,165        64,441  
  
 
 
    
 
 
 
Income from operations
     872        12,616  
  
 
 
    
 
 
 
Other expense, net:
     
Interest expense
     (737      (2,470
Other expense, net
     (3      (3
  
 
 
    
 
 
 
Total other expense, net
     (740      (2,473
  
 
 
    
 
 
 
Net income before income taxes
     132        10,143  
Income tax expense
     (45      (200
  
 
 
    
 
 
 
Net income
   $ 87      $ 9,943  
  
 
 
    
 
 
 
EBITDA and Adjusted EBITDA
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results.
These non-GAAP financial
measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
 
25

Table of Contents
The following is a reconciliation of GAAP net income to
non-GAAP
EBITDA and
non-GAAP
Adjusted EBITDA for each of the periods presented:
 
    
Three Months Ended

March 31,
 
    
2022
    
2021
 
Net income
   $ 87      $ 9,943  
Interest expense
     737        2,470  
Income tax expense
     45        200  
Depreciation
     1,347        1,010  
Amortization
     1,221        1,243  
  
 
 
    
 
 
 
EBITDA
     3,437        14,866  
  
 
 
    
 
 
 
Stock-based compensation expense
     1,303        698  
Recovery of certain notes receivable from related parties (1)
     —          (179
Change in fair value of Earnout (2)
     —          (296
Restructuring charge (3)
     264        927  
  
 
 
    
 
 
 
Adjusted EBITDA
   $ 5,004      $ 16,016  
  
 
 
    
 
 
 
 
(1)
Amount reflects the collection of certain notes receivable from related parties previously reserved. See Note “19. Related Party Transactions”.
(2)
Amount reflects the change in the fair value of the Earnout liability in connection with the CPN acquisition. See Note “3. Acquisition” and “5. Fair Value Measurement of Financial Assets and Liabilities”.
(3)
Amount reflects employee retention and benefits as well as the facility-related cost related to the Company’s restructuring activities. See Note “12. Restructuring”.
Comparison of the Three Months Ended March 31, 2022 and 2021
Revenue
 
    
Three Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
           
    
(in thousands, except for percentages)
 
Advanced Wound Care
   $ 90,950      $ 90,708      $ 242        0
Surgical & Sports Medicine
     7,167        11,844        (4,677      (39 %) 
  
 
 
    
 
 
    
 
 
    
 
 
 
Net revenue
   $ 98,117      $ 102,552      $ (4,435      (4 %) 
  
 
 
    
 
 
    
 
 
    
 
 
 
Net revenue from our Advanced Wound Care products in the three months ended March 31, 2022 was $91.0 million, relatively consistent with the net revenue of $90.7 million in the three months ended March 31, 2021.
Net revenue from our Surgical & Sports Medicine products decreased by $4.7 million, or 39%, to $7.2 million in the three months ended March 31, 2022 from $11.8 million in the three months ended March 31, 2021. The decrease in Surgical & Sports Medicine net revenue was primarily due to the continued impact of the suspension of marketing of our ReNu and NuCel products in connection with the expiration of the FDA’s enforcement grace period on May 31, 2021 and, to a lesser extent, the impact of the
COVID-19
pandemic on sales of our Affinity product.
Included within net revenue is PuraPly revenue of $53.3 million and $41.3 million for the three months ended March 31, 2022 and 2021, respectively. The continued increase in PuraPly revenue in the three months ended March 31, 2022 was due to our expanded sales force, expanded sites of care, and increased adoption, by existing and new customers, of our PuraPly line extensions.
 
26

Table of Contents
Cost of goods sold and gross profit
 
                                                   
    
Three Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
           
    
(in thousands, except for percentages)
 
Cost of goods sold
  
$
25,080
 
  
$
25,495
 
  
$
(415
  
 
(2
%) 
  
 
 
    
 
 
    
 
 
    
 
 
 
Gross profit
  
$
73,037
 
  
$
77,057
 
  
$
(4,020
  
 
(5
%) 
  
 
 
    
 
 
    
 
 
    
 
 
 
Cost of goods sold decreased by $0.4 million, or 2%, to $25.1 million in the three months ended March 31, 2022 from $25.5 million in the three months ended March 31, 2021. The decrease in cost of goods sold was primarily due to decreased unit volumes in Surgical & Sports Medicine products.
Gross profit decreased by $4.0 million, or 5%, to $73.0 million in the three months ended March 31, 2022 from $77.1 million the three months ended March 31, 2021. The decrease in gross profit resulted primarily from decreased sales volume in Surgical & Sports Medicine products as well as increased manufacturing-related costs.
Research and Development Expenses
 
                                                   
    
Three Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
           
    
(in thousands, except for percentages)
 
Research and development
  
$
8,587
 
  
$
6,209
 
  
$
2,378
 
  
 
38
  
 
 
    
 
 
    
 
 
    
 
 
 
Research and development expenses increased by $2.4 million, or 38%, to $8.6 million in the three months ended March 31, 2022 from $6.2 million in the three months ended March 31, 2021. The increase in research and development expenses was primarily due to increased headcount associated with our existing Advanced Wound Care and Surgical & Sports Medicine products, an increase in product costs associated with our pipeline products not yet commercialized and an increase in the clinical study and related costs necessary to seek regulatory approvals for certain of our products.
Selling, General and Administrative Expenses
 
              
              
              
              
    
Three Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
           
    
(in thousands, except for percentages)
 
Selling, general and administrative
  
$
63,578
 
  
$
58,232
 
  
$
5,346
 
  
 
9
  
 
 
    
 
 
    
 
 
    
 
 
 
Selling, general and administrative expenses increased by $5.3 million, or 9%, to $63.6 million in the three months ended March 31, 2021 from $58.2 million in the three months ended March 31, 2020. The increase in selling, general and administrative expenses was primarily due to a $4.1 million increase related to additional headcount, primarily in our direct sales force, and a $2.0 million increase related to increased travel and marketing programs amid
the relaxed COVID-19 travel
restrictions. These increases were partially offset by a $0.7 million decrease in restructuring costs due to the substantial completion of the restructuring activities associated with closing the La Jolla, California office.
 
27

Table of Contents
Other Expense, net
 
                                                   
    
Three
Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
                             
    
(in thousands, except for percentages)
 
Interest expense, net
  
$
(737
  
$
(2,470
  
$
1,733
 
  
 
(70
%) 
Other expense, net
  
 
(3
  
 
(3
  
 
—  
 
  
 
**
 
  
 
 
    
 
 
    
 
 
    
 
 
 
Total other expense, net
  
$
(740
  
$
(2,473
  
$
1,733
 
  
 
(70
%) 
  
 
 
    
 
 
    
 
 
    
 
 
 
 
**
not meaningful
Other expense, net, decreased by $1.7 million, or 70%, to $0.7 million in the three months ended March 31, 2022 from $2.5 million in the three months ended March 31, 2021. Interest expense decreased due to the reduced interest rate for borrowings under the 2021 Credit Agreement.
Income Tax Expense
 
            
            
            
            
    
Three Months Ended
March 31,
    
Change
 
    
2022
    
2021
    
$
    
%
 
                             
    
(in thousands, except for percentages)
 
Income tax expense
  
$
(45
  
$
(200
  
$
155
 
  
 
(78
%) 
  
 
 
    
 
 
    
 
 
    
 
 
 
Income tax expense decreased by $0.2 million, or 78% to $0.0 million in the three months ended March 31, 2022 from $0.2 million in the three months ended March 31, 2021. The decrease in the provision is primarily attributed to the decrease in taxable income from $10.1 million in the three months ended March 31, 2021 to $0.1 million in the three months ended March 31, 2022. The decrease in taxable income is partially offset by the increase in the effective rate from 2.19% in the three months ended March 31, 2021 to 26.65% in the three months ended March 31, 2022 due to the release of the valuation allowance in the three months ended December 31, 2021.
Liquidity and Capital Resources
Since our inception, we have funded our operations and capital expenditures through cash flows from product sales, loans from affiliates and entities controlled by certain of our affiliates, third-party debt and proceeds from the sale of our capital stock. As of March 31, 2022, we had an accumulated deficit of $60.0 million and working capital of $141.1 million which included $107.9 million in cash and cash equivalents. We also had $125,000 available for future revolving borrowings under our Revolving Facility (see Note “13. Long-Term Debt Obligations”). For the three months ended March 31, 2022, we reported $98.1 million in net revenue, $0.1 million in net income and $1.4 million of cash flows from operating activities. We expect that our cash on hand and other components of working capital as of March 31, 2022, availability under the 2021 Credit Agreement, plus net cash flows from product sales, will be sufficient to fund our operating expenses, capital expenditure requirements and debt service payments for at least 12 months beyond the filing date of this quarterly report.
We continue to closely monitor ongoing developments in connection with the
COVID-19
pandemic, which may negatively impact our commercial prospects, cash position and access to capital in fiscal 2022 or beyond. We will continue to assess our cash and other sources of liquidity and, if circumstances warrant, we will make appropriate adjustments to our operating plan.
Our primary uses of cash are working capital requirements, capital expenditure and debt service payments. Additionally, from time to time, we may use capital for acquisitions and other investing and financing activities. Working capital is used principally for our personnel as well as manufacturing costs related to the production of our products. Our working capital requirements vary from period to period depending on manufacturing volumes, the timing of shipments and the payment cycles of our customers and payers. Our capital expenditures consist primarily of building improvements, manufacturing equipment, and computer hardware and software.
To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through additional equity or debt financings, other strategic transactions or a combination of these potential sources of funds. There can be no assurance that we will be able to obtain additional funds on terms acceptable to us, on a timely basis or at all.
 
28

Table of Contents
Cash Flows
The following table summarizes our cash flows for each of the periods presented:
 
    
Three Months Ended
March 31,
 
    
2022
    
2021
 
    
(in thousands)
 
Net cash provided by (used in) operating activities
   $ 1,411      $ (1,300
Net cash used in investing activities
     (6,672      (4,957
Net cash used in financing activities
     (765      (591
  
 
 
    
 
 
 
Net change in cash, cash equivalents, and restricted cash
   $ (6,026    $ (6,848
  
 
 
    
 
 
 
Operating Activities
During the three months ended March 31, 2022, net cash provided by operating activities was $1.4 million, resulting from our net income of $0.1 million and
non-cash
charges of $8.2 million, partially offset by cash used in connection with changes in our operating assets and liabilities of $6.9 million. Net cash used in changes in our operating assets and liabilities included an increase in prepaid expenses and other current assets of $2.2 million, a decrease in operating leases liability of $1.8 million, a decrease in accounts payable of $1.2 million, and a decrease in accrued expenses and other current liabilities of $4.8 million, all of which were partially offset by a decrease in accounts receivable of $2.9 million.
During the three months ended March 31, 2021, net cash used in operating activities was $1.3 million, resulting from our net cash used in connection with changes in our operating assets and liabilities of $19.1 million, partially offset by net income of $9.9 million
and non-cash charges
of $7.8 million. Net cash used in changes in our operating assets and liabilities included an increase in accounts receivable of $16.1 million, an increase in inventory of $4.2 million, an increase in prepaid expenses and other current assets of $0.6 million, and a decrease in operating leases and other liabilities of $1.4 million, all of which were partially offset by an increase in accounts payable of $1.8 million, and an increase of accrued expenses and other current liabilities of $1.4 million.
Investing Activities
During the three months ended March 31, 2022, we used $6.7 million of cash in investing activities consisting exclusively of capital expenditures.
During